Aquestive Therapeutics to Present at Four Major Healthcare Investor Conferences in March

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Aquestive Therapeutics will present at four major healthcare investor conferences in March 2026, updating investors on its clinical pipeline and strategic initiatives.

Aquestive Therapeutics to Present at Four Major Healthcare Investor Conferences in March

Aquestive Therapeutics announced plans to present at four prominent investor conferences scheduled for March 2026, positioning the company to engage with institutional investors and healthcare analysts across the sector. The pharmaceutical company's management team will participate in the TD Cowen, Leerink Partners, Citizens Life Sciences, and Barclays healthcare conferences, providing updates on its clinical pipeline and strategic business initiatives.

The conference participation will include formal presentations as well as one-on-one meetings with investors, offering a comprehensive platform to discuss the company's development programs and operational progress. This investor outreach activity is a standard practice for public biotech companies seeking to maintain regular communication with capital markets and update stakeholders on pipeline advancements.

The March conference schedule represents a key opportunity for Aquestive to engage with a diverse investor audience during a period when the biotech sector typically hosts multiple healthcare-focused investor forums.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 25

Related Coverage

GlobeNewswire Inc.

XORTX Shareholders Back 5-to-1 Consolidation to Avert NASDAQ Delisting

XORTX shareholders approved a 5-to-1 share consolidation to maintain NASDAQ compliance, reducing shares from 6.96M to 1.39M ahead of April 2026 deadline.

XRTX
GlobeNewswire Inc.

Aquestive Faces Securities Fraud Suit Over Anaphylm FDA Misrepresentation

Aquestive Therapeutics faces securities fraud lawsuit after FDA rejected Anaphylm drug, contradicting management's prior "on track" statements; $AQST stock fell 37%.

AQST
GlobeNewswire Inc.

Lifecore Biomedical Lands Third Commercial Site Transfer in Medical Aesthetics Push

Lifecore Biomedical announces third commercial CDMO site transfer since October 2025, targeting 12% revenue CAGR through 2029.

LFCR
GlobeNewswire Inc.

Securities Lawsuit Filed Against Aquestive Over Anaphylm Drug Application Misstatements

Rosen Law Firm seeks lead plaintiffs in securities lawsuit against Aquestive Therapeutics over alleged false statements regarding Anaphylm drug application.

AQST
The Motley Fool

Maze Therapeutics President Liquidates Full Position Ahead of Q4 Earnings

Maze Therapeutics president Harold Bernstein sold all 30,000 shares for $1.51M via pre-arranged trading plan, weeks before Q4 earnings report.

MAZE
GlobeNewswire Inc.

Aquestive Names New Chief Legal Officer as Braender Transitions to Corporate Secretary

Aquestive Therapeutics appoints Day Pitney partner Thomas Zalewski as Chief Legal Officer and Chief Compliance Officer, with Lori Braender transitioning to Corporate Secretary after eight years.

AQST